Navigation Links
AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs
Date:7/23/2008

WILMINGTON, Del., July 23 /PRNewswire-FirstCall/ -- More than a third of the people who contacted AstraZeneca (NYSE: AZN) to inquire about the company's prescription savings programs learned of the programs from their doctors or pharmacists, according to a year-long survey of more than 12,000 patients.

The survey found that 35 percent of the patients who called AstraZeneca's information center regarding prescription savings programs said they were referred by healthcare professionals. Another 14 percent learned of the program from brochures, which also are available in doctors' offices, hospitals, clinics and pharmacies.

"AstraZeneca understands that our medicines don't do patients any good if they cannot afford to pay for them," said Tony Zook, President and CEO, AstraZeneca North America. "We connect families with our patient assistance programs in a variety of ways, but our most valuable tool is providing doctors and pharmacists with the information they need to help their patients."

As they meet with healthcare providers, AstraZeneca's pharmaceutical sales specialists share up-to-date clinical information on medicines and other issues impacting patient care, including adherence, educational materials and prescription savings programs.

The study's data shows that the message on patient assistance programs is getting through in a variety of ways. AstraZeneca asked 12,487 patients who contacted its information center between April 2007 and March 2008 where they learned about the company's patient assistance programs. The results:

-- Doctor/pharmacist 35 percent

-- Brochure 14 percent

-- Advertising 9 percent

-- AZ Web sites 7 percent

-- Community programs 6 percent

-- Family/friend 5 percent

-- Other/don't know 24 percent

Patients who cited advertising said they learned of the program from a variety of newspaper, radio and television ads. AstraZeneca was the first in the industry to promote its prescription savings programs in its product television ads. Television ads for NEXIUM started carrying the message in April 2005, and all of AstraZeneca's product television ads have included the information since then. Previous research shows that including this information in our advertising significantly raised awareness and the impact of AstraZeneca's patient assistance program among the public.

AstraZeneca has offered prescription savings programs side by side with its medicines for three decades and now offers one of the industry's most generous programs. People without insurance who earn up to $30,000 for an individual and $60,000 for a family of four may be eligible for help from AstraZeneca.

In 2007 alone, AstraZeneca helped nearly half a million people fill 2.8 million prescriptions, resulting in more than $500 million of savings to patients. AstraZeneca offers help under the AZ&Me Prescription Savings programs, including support for people without insurance, people with Medicare Part D and a third program that provides medicines to healthcare facilities.

Patients can learn more about the AZ&Me Prescription Savings program at http://www.azandme.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit http://www.astrazeneca-us.com .


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
4. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
5. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
6. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
7. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
8. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
9. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
10. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... The Greater ... a new partnership with Compass Research . GGI's mission is to advance global ... to a child in need in honor of each clinical trial volunteer. The vision ...
(Date:2/23/2017)... , Feb. 23, 2017 Aviva ... tools, announced the acquisition of GenWay Biotech Incorporated, ... comprehensive service and product offering for both the ... will facilitate growth and enhance capabilities for both ... and ELISA assays will nicely complement ASB,s objective ...
(Date:2/23/2017)... USA, and CARDIFF, UK (PRWEB) , ... February ... ... international society for optics and photonics , have been named Fellows of the ... significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and ...
(Date:2/22/2017)... LOS ANGELES, CA (PRWEB) , ... February 22, ... ... company, today announced that is has acquired Kendall Research Systems, LLC ... of Technology (MIT) that develops neural interface technology for research and clinical applications. ...
Breaking Biology Technology:
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):